Working with C57BL/6 mouse tumor models, we had previously demonstrated that vaccination with IgE-coated tumor cells can protect against tumor challenge, an observation that supports the involvement of IgE in antitumor immunity. The adjuvant effect of IgE was shown to result from eosinophil-dependent priming of the T cell-mediated adaptive immune response. The protective effect is likely to be mediated by the interaction of tumor cell-bound IgE with receptors, which then trigger the release of mediators, recruitment of effector cells, cell killing and tumor Ag cross-priming. It was therefore of utmost importance to demonstrate the strict dependence of the protective effect on IgE receptor activation. First, the protective effect of IgE was confirmed in a BALB/c tumor model, in which IgE-loaded modified VV Ankara-infected tumor cells proved to be an effective cellular vaccine. However, the protective effect was lost in Fc(epsilon)RIalpha(-/-) (but not in CD23(-/-)) knockout mice, showing the IgE-Fc(epsilo)nRI interaction to be essential. Moreover, human IgE (not effective in BALB/c mice) had a protective effect in the humanized knockin mouse (Fc(epsilon)RIalpha(-/-) hFc(epsilon)RIalpha(+)). This finding suggests that the adjuvant effect of IgE could be exploited for human therapeutics.
Antitumor IgE adjuvanticity : key role of Fc epsilon RI / E.A. Nigro, A.T. Brini, E. Soprana, A. Ambrosi, D. Dombrowicz, A. Siccardi, L. Vangelista. - In: JOURNAL OF IMMUNOLOGY. - ISSN 0022-1767. - 183:7(2009 Oct), pp. 4530-4536.
|Titolo:||Antitumor IgE adjuvanticity : key role of Fc epsilon RI|
NIGRO, ELISA AGNESE (Primo)
BRINI, ANNA TERESA (Secondo)
SICCARDI, ANTONIO (Penultimo)
VANGELISTA, LUCA (Ultimo)
|Settore Scientifico Disciplinare:||Settore BIO/13 - Biologia Applicata|
|Data di pubblicazione:||ott-2009|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.4049/jimmunol.0900842|
|Appare nelle tipologie:||01 - Articolo su periodico|